News
Prostate cancer patients left navigating "knowledge gap" over treatment options
1+ hour, 43+ min ago (764+ words) Prostate cancer is the most commonly diagnosed cancer in the UK, with more than 63, 000 new cases each year. Yet for many men, understanding their treatment options remains far from straightforward New research commissioned by Genesis Care, the UK's largest independent,…...
Novartis' Pluvicto Shows Lower Risk Of PSA Progression In Phase 3 PSMAddition Trial For MHSPC
5+ min ago (464+ words) Data were presented as a rapid oral presentation at the American Urological Association Annual Meeting 2026. Novartis focuses on developing radioligand therapy (RLT) for cancer treatment. By harnessing the power of targeted radiation, RLT is designed to deliver treatment directly to…...
Novartis - Data Shows 58% Lower Risk Of Psa Progression With Pluvicto In Prostate Cancer
5+ hour, 26+ min ago (33+ words) Trading View Novartis - Data Shows 58% Lower Risk Of Psa Progression With Pluvicto In Prostate Cancer More news from Reuters...
Advances In Diagnosis And Treatment
3+ hour, 28+ min ago (224+ words) This final research blog will focus on two tests (liquid biopsies and patient-derived organoids) that are being trialled for the diagnosis and follow up of prostate cancer. There is also a spotlight on two novel therapeutic approaches (an immunotherapy agent…...
Frontiers | Integrative oncology along with systemic cancer therapies in advanced bladder and prostate cancer: metabolic optimization guiding the shift from palliative care to clinical remission " a case report
4+ hour, 3+ min ago (444+ words) Hundred Years of The Warburg Effect, Metabolic Hallmark of Cancer Cells: Progress in the Prevention, Treatment and Targeted Therapy of Cancer Front. Oncol. , 18 May 2026 The patient then decided against undergoing chemotherapy and went for self-herbal remedies for 4 months (October 2023- March…...
Doctors may have found an easier way to treat prostate cancer " could become new "standard of care" - AOL
10+ hour, 57+ min ago (542+ words) Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, prostate cancer often comes with traditional treatments that cause difficult side effects. Now, a recent study…...
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA" (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
6+ hour, 23+ min ago (666+ words) WHIPPANY, N. J. --(BUSINESS WIRE)--New data from the Phase II ARASEC trial show NUBEQA" (darolutamide) plus androgen deprivation therapy (ADT) resulted in a 71% reduction in the risk of progression or death per CHAARTED criteria compared to ADT alone (HR 0. 29; 95% CI 0. 200. 40; P…...
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto" in metastatic hormone-sensitive prostate cancer " Weekly Voice
15+ hour, 42+ min ago (87+ words) New PSMAddition data show 58% lower risk of PSA progression with Pluvicto" in metastatic hormone-sensitive prostate cancer Weekly Voice The Largest South Asian News Platforms since 1997 Basel, May 17, 2026 " Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses…...
AI Tool in Radiotherapy Advances Global Fight to Eradicate Cervical Cancer
10+ hour, 29+ min ago (1116+ words) Bioengineer. org AI Tool in Radiotherapy Advances Global Fight to Eradicate Cervical Cancer A groundbreaking international clinical trial led by researchers at University College London (UCL) and the London School of Hygiene & Tropical Medicine (LSHTM) has demonstrated the striking effectiveness…...
When should you get a mammogram? Conflicting advice makes it hard to know
11+ hour, 30+ min ago (922+ words) WASHINGTON " Deciding when to get routine mammograms is confusing. Some health groups recommend women begin at age 40 or 45 while another recently opted for age 50. They also differ on whether yearly or every other year is best. The conflicting advice is…...